Skip to main contentAdvertisementThe Guardian – Back to homeSupport The GuardianAvailable for everyone, funded by readersContributeSubscribeSearch jobsSign inSearch current edition:International edition
Gene editing will let us control our very evolution. Will we use it wisely?
I’ve covered some of the biggest stories of our age, but this is the biggest and could change what it means to be human
Sun 8 Dec 2019 08.15 GMTLast modified on Sun 8 Dec 2019 08.24 GMT
We live in a time when science and technology are having an impact on our society in more and more ways. And the decisions that shape how these new fields of knowledge develop ultimately affect all of us.
4 out of 5 stars. Read more
When I studied biology in high school, I didn’t learn about DNA for a very simple reason. The work of Francis Crick, James Watson, Rosalind Franklin and others who unlocked the structure of the basic code of life was still years away. The idea of engineering human beings? Well, that was firmly the stuff of science fiction, like Aldous Huxley’s dystopian novel Brave New World (published a year after my birth). It seemed as likely as, say, going to the moon.
There are a few inferences you can make from this framing of my life. One is that I have been on the planet for a while. The other is the speed of change in what we know about what life is, and how we can control it, has accelerated at a rapid rate. Now we as a species are on the precipice of being able to manipulate the very building blocks of human evolution, not to mention wield unpredictable change on the greater world around us. Even as I commit that thought to paper, I pause in awe at its implications.
I have lived through eventful times and my job as a journalist has been to chronicle wars, presidents and sweeping social movements such as civil rights. I have seen a world in flux, but when I try to peer into the future I come to the conclusion that this story of humankind’s ability to understand life on its most intimate level and be able to tinker with it for our benefit or detriment is likely to be the biggest one I will ever cover.
We are living in one of the greatest epochs of human exploration and it will shape our world as profoundly as the age of the transoceanic explorers. It is just that the beachheads on which we are landing and the continents we are mapping comprise a world far too small to see with the naked eye. Some of it is even invisible to our most powerful microscopes.
This brings me to a term that has become a big part of my life over the last few years: Crispr. Perhaps you know of it. Perhaps you don’t. When I first heard of it, I thought it might be a new brand of toaster. I now know it’s an extremely powerful tool for editing genes in seemingly any organism on Earth, including humans. Scientists doing basic research have been uncovering the mechanisms of life for decades. They have been creating tools for modifying individual genes but Crispr is one of those revolutions where what researchers thought might be possible in the distant horizon is suddenly available now. It’s cheap, it’s relatively simple and it’s remarkably precise.
I immediately knew that this was a story that needed telling. Human Nature, the resulting film – full disclosure, I am executive producer – came out of our conversations with scientists. They tend not to be the type of people who hype things but when they talk about Crispr you can feel the urgency in their voices. This is something you need to know about. All of you. If you are worried about your health or the health of your children. If you are concerned about how we might need to engineer our planet in the face of the climate crisis. If you are in finance, law or the world of tech. This will shape all of it.
And as we grapple with the unintended consequences of the internet and social media, as we try to make progress against a heating planet, I humbly submit that we as a species tend not to be good at thinking through where we are going until a crisis is already upon us. I fervently hope with Crispr that we can start the conversation sooner. That we can start it now. That’s why we made the film.
To be clear, we are probably a long way from designing babies to be more intelligent or more musically inclined. Life is just too complex for that, at least right now. More immediately, there is so much about this technology that is very exciting. As someone who remembers a time when my classmates were struck down with childhood diseases for which we now have vaccines, I know science can have profound applications for human health. Crispr could cure genetic diseases such as sickle cell and Huntington’s. It is being tested against cancers and HIV. It could also potentially be used to make crops more drought-resistant or food more nutritious.
On the other hand, we are walking closer to a world Aldous Huxley foresaw. What does it mean to be human? Where should we draw the boundaries beyond which we dare not cross? The inspiring researchers we talked to for the film know that the ethical and moral questions this technology raises are not for them to decide. Science has given us the tools, but not the answers. This is up to us, all of us. We need to be informed. We need to be honest with what’s real and what’s not. And we need to add our voices to a global conversation. That’s part of our responsibility as humans living on Earth today.
Dan Rather is one of the US’s most feted journalists. He anchored CBS Evening News for 24 years
Human Nature is in UK cinemas now before a university town tour in the new year, wondercollaborative.org/human-nature-documentary-film/#screenings . It will be shown on BBC Storyville in spring/summer 2020
Since you’re here…
… we have a small favour to ask. More people, like you, are reading and supporting the Guardian’s independent, investigative journalism than ever before. And unlike many news organisations, we made the choice to keep our reporting open for all, regardless of where they live or what they can afford to pay.
The Guardian will engage with the most critical issues of our time – from the escalating climate catastrophe to widespread inequality to the influence of big tech on our lives. At a time when factual information is a necessity, we believe that each of us, around the world, deserves access to accurate reporting with integrity at its heart.
Our editorial independence means we set our own agenda and voice our own opinions. Guardian journalism is free from commercial and political bias and not influenced by billionaire owners or shareholders. This means we can give a voice to those less heard, explore where others turn away, and rigorously challenge those in power.
We hope you will consider supporting us today. We need your support to keep delivering quality journalism that’s open and independent. Every reader contribution, however big or small, is so valuable. Support The Guardian from as little as $1 – and it only takes a minute. Thank you.Support The Guardian
interruption on all
- Rapper Juice WRLD dies aged 21
- Austria struggles with marauding Krampus demons gone rogue
- Impeachment inquiry: Nadler may add Mueller counts against Trump
- Donald Trump has destroyed American leadership – I’ll restore itElizabeth Warren
- Fit for stardom: How Adam Driver went from US Marine to Hollywood heartthrob
- Guardian PickAny talk of practical applications for molecular biology technologies is way premature. Off target effects common in gene editing methods will not be removed for a long time to come, and I cannot for the life of me understand why scientific reporting is so uncritical. As a Molecular biologist and now Professor of Molecular Medicine I have worked with molecular techniques for the last 40 years and even basic methods such as PCR, reverse transcript…Jump to commentStephenBustin15h ago1516
- Guardian PickAgain, an article implying that CRISPR can affect intelligence or creativity.It cannot.CRISPR edits one specific gene section. That is all.We do not have an “Intelligence” gene section. Therefore CRISPR cannot promote intelligence. Ditto “Musicality” or “Beauty”.If, however, you want your foetus to have blue eyes instead of brown, then eventually you might be able to do that.Eventually, if we do manage to lock down the sequences for resistan…Jump to commentSethis215h ago1516
View more comments
- Contact us
- Complaints & corrections
- Work for us
- Terms & conditions
Help us improve our products. Sign up to take part.
- Review Article
- Published: 02 December 2019
CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment
- 178 Accesses
- 1 Altmetric
Cancer is a highly heterogeneous disease in term of molecular signature even though it is originated from the same tissue type. Cancer heterogeneity may occur during its development or treatment, which is the main cause resulting in drug resistance and recurrence. Precision medicine refers to matching the right medicine to the right patients based on their molecular signatures. Therefore, a thorough understanding of the mechanism of tumorigenesis and drug resistance is essential to precision medicine. CRISPR-cas9 system is a powerful tool for gene editing and CRISPR-based high-throughput screening has been widely applied especially in searching for tumor-driven or synergistic lethal genes aiming to overcome drug resistance. In this review, we describe the progress of CRISPR-cas9-based unbiased screening in precision medicine including identification of new drug targets, biomarkers and elucidation of mechanisms leading to drug resistance. The existing challenges as well as the future directions are also discussed.
Subscribe to Journal
Get full journal access for 1 year
only $57.00 per issueSubscribe
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
from$8.99Rent or Buy
All prices are NET prices.
Additional access options:
- 1.Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
- 2.Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481:306–13.
- 3.McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168:613–28.
- 4.Kampmann M, Horlbeck MA, Chen YW, Tsai JC, Bassik MC, Gilbert LA, et al. Next-generation libraries for robust RNA interference-based genome-wide screens. Proc Natl Acad Sci U S A. 2015;112:E3384–E91.
- 5.Fennell M, Xiang Q, Hwang A, Chen C, Huang CH, Chen CC, et al. Impact of RNA-guided technologies for target identification and deconvolution. J Biomol Screen. 2014;19:1327–37.
- 6.Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. Nat Rev Genet. 2010;11:636–46.
- 7.Joung JK, Sander JD. INNOVATION TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol. 2013;14:49–55.
- 8.Gaj T, Gersbach CA, Barbas CF. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013;31:397–405.
- 9.Koo T, Lee J, Kim JS. Measuring and reducing off-target activities of programmable nucleases including CRISPR-Cas9. Mol Cells. 2015;38:475–81.
- 10.Heck D, Kowalczyk MS, Yudovich D, Belizaire R, Puram RV, McConkey ME, et al. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat Biotechnol. 2014;32:941–6.
- 11.Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343:84–7.
- 12.Chen SD, Sanjana NE, Zheng KJ, Shalem O, Lee K, Shi X, et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell. 2015;160:1246–60.
- 13.Lin KH, Xie A, Rutter JC, Ahn YR, Lloyd-Cowden JM, Nichols AG, et al. Systematic dissection of the metabolic-apoptotic interface in AML reveals heme biosynthesis to be a regulator of drug sensitivity. Cell Metab. 2019;29:1217–31.
- 14.Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816–21.
- 15.Heler R, Marraffini LA, Bikard D. Adapting to new threats: the generation of memory by CRISPR-Cas immune systems. Mol Microbiol. 2014;93:1–9.
- 16.Mojica FJM, Rodriguez-Valera F. The discovery of CRISPR in archaea and bacteria. FEBS J. 2016;283:3162–9.
- 17.Garneau JE, Dupuis ME, Villion M, Romero DA, Barrangou R, Boyaval P, et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature. 2010;468:67–71.
- 18.Gasiunas G, Barrangou R, Horvath P, Siksnys V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci U S A. 2012;109:E2579–E86.
- 19.Hale CR, Zhao P, Olson S, Duff MO, Graveley BR, Wells L, et al. RNA-guided RNA cleavage by a CRISPR RNA-Cas protein complex. Cell. 2009;139:945–56.
- 20.Jiang FG, Doudna JA. The structural biology of CRISPR-Cas systems. Curr Opin Struct Biol. 2015;30:100–11.
- 21.Lieber MR. The mechanism of double-strand dna break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem. 2010;79:181–211.
- 22.Koonin EV, Makarova KS, Zhang F. Diversity, classification and evolution of CRISPR-Cas systems. Curr Opin Microbiol. 2017;37:67–78.
- 23.Jiang FG, Doudna JA. CRISPR-Cas9 structures and mechanisms. Annu Rev Biophys. 2017;46:505–29.
- 24.van der Oost J, Westra ER, Jackson RN, Wiedenheft B. Unravelling the structural and mechanistic basis of CRISPR-Cas systems. Nat Rev Microbiol. 2014;12:479–92.
- 25.Wiedenheft B, Sternberg SH, Doudna JA. RNA-guided genetic silencing systems in bacteria and archaea. Nature. 2012;482:331–8.
- 26.Zhan TZ, Rindtorff N, Betge J, Ebert MP, Boutros M. CRISPR/Cas9 for cancer research and therapy. Semin Cancer Biol. 2019;55:106–19.
- 27.Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C, et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature. 2015;517:583–U332.
- 28.Ahmad G, Amiji M. Use of CRISPR/Cas9 gene-editing tools for developing models in drug discovery. Drug Discov Today. 2018;23:519–33.
- 29.Hasson SA, Kane LA, Yamano K, Huang CH, Sliter DA, Buehler E, et al. High-content genome-wide RNAi screens identify regulators of parkin upstream of mitophagy. Nature. 2013;504:291–5.
- 30.Shalem O, Sanjana NE, Zhang F. High-throughput functional genomics using CRISPR-Cas9. Nat Rev Genet. 2015;16:299–311.
- 31.Malina A, Mills JR, Cencic R, Yan YF, Fraser J, Schippers LM, et al. Repurposing CRISPR/Cas9 for in situ functional assays. Gene Dev. 2013;27:2602–14.
- 32.Zhou PH, Shaffer DR, Arias DAA, Nakazaki Y, Pos W, Torres AJ, et al. In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature. 2014;506:52-7.
- 33.Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, et al. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell. 2015;163:1515–26.
- 34.Munoz DM, Cassiani PJ, Li L, Billy E, Korn JM, Jones MD, et al. CRISPR screens provide a comprehensive assessment of cancer vulnerabilities but generate false-positive hits for highly amplified genomic regions. Cancer Discov. 2016;6:900–13.
- 35.Shi JW, Wang E, Milazzo JP, Wang ZH, Kinney JB, Vakoc CR. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat Biotechnol. 2015;33:661–7.
- 36.Yau EH, Kummetha IR, Lichinchi G, Tang R, Zhang YL, Rana TM. Genome-wide CRISPR screen for essential cell growth mediators in mutant KRAS colorectal cancers. Cancer Res. 2017;77:6330–9.
- 37.Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, et al. A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia. Cell Rep. 2016;17:1193–205.
- 38.Behan FM, Iorio F, Picco G, Goncalves E, Beaver CM, Migliardi G, et al. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature. 2019;568:511.
- 39.Winters IP, Murray CW, Winslow MM. Towards quantitative and multiplexed in vivo functional cancer genomics. Nat Rev Genet. 2018;19:741–55.
- 40.Xu CL, Qi XL, Du XG, Zou HY, Gao F, Feng T, et al. piggyBac mediates efficient in vivo CRISPR library screening for tumorigenesis in mice. Proc Natl Acad Sci U S A. 2017;114:722–7.
- 41.Zheng YZ, Xue MZ, Shen HJ, Li XG, Ma D, Gong Y, et al. PHF5A epigenetically inhibits apoptosis to promote breast cancer progression. Cancer Res. 2018;78:3190–206.
- 42.Brunen D, de Vries RC, Lieftink C, Beijersbergen RL, Bernards R. PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma. Mol Cancer Ther. 2018;17:849–57.
- 43.Wang C, Jin HJ, Gao DM, Lieftink C, Evers B, Jin GZ, et al. Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer. J Hepatol. 2018;69:1057–65.
- 44.McCleland ML, Mesh K, Lorenzana E, Chopra VS, Segal E, Watanabe C, et al. CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Investig. 2016;126:639–52.
- 45.Oser MG, Fonseca R, Chakraborty AA, Brough R, Spektor A, Jennings RB, et al. Cells lacking the RB1 tumor suppressor gene are hyperdependent on Aurora B kinase for survival. Cancer Discov. 2019;9:230–47.
- 46.Goodspeed A, Jean A, Costello JC. A whole-genome CRISPR screen identifies a role of MSH2 in cisplatin-mediated cell death in muscle-invasive bladder cancer. Eur Urol. 2019;75:242–50.
- 47.Goncalves E, Behan FM, Louzada S, Arnol D, Stronach EA, Yang FT, et al. Structural rearrangements generate cell-specific, gene-independent CRISPR-Cas9 loss of fitness effects. Genome Biol. 2019;20:27. https://doi.org/10.1186/s13059-019-1637-z.
- 48.Sanson KR, Hanna RE, Hegde M, Donovan KF, Strand C, Sullender ME, et al. Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities. Nat Commun. 2018;9:5416. https://doi.org/10.1038/s41467-018-07901-8.
- 49.Zhang XY, Choi PS, Francis JM, Gao GF, Campbell JD, Ramachandran A, et al. Somatic superenhancer duplications and hotspot mutations lead to oncogenic activation of the KLF5 transcription factor. Cancer Discov. 2018;8:108–25.
- 50.Barazas M, Annunziato S, Pettitt SJ, de Krijger I, Ghezraoui H, Roobol SJ, et al. The CST complex mediates end protection at double-strand breaks and promotes PARP inhibitor sensitivity in BRCA1-deficient cells. Cell Rep. 2018;23:2107–18.
- 51.Zimmermann M, Murina O, Reijns MAM, Agathanggelou A, Challis R, Tarnauskaite Z, et al. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions. Nature. 2018;559:285–9.
- 52.Kanarek N, Keys HR, Cantor JR, Lewis CA, Chan SH, Kunchok T, et al. Histidine catabolism is a major determinant of methotrexate sensitivity. Nature. 2018;559:632–6.
- 53.Shang WJ, Jiang Y, Boettcher M, Ding K, Mollenauer M, Liu ZY, et al. Genome-wide CRISPR screen identifies FAM49B as a key regulator of actin dynamics and T cell activation. Proc Natl Acad Sci U S A. 2018;115:E4051–E60.
- 54.Veo B, Fosmire S, Wang D, Madhavan K, Pierce A, Venkataraman S, et al. Functional CRISPR-Cas9 screen identifies druggable dependencies in Myc-driven medulloblastoma. Neuro Oncol. 2019;21(Suppl 2):105–6.
- 55.Gallipoli P, Giotopoulos G, Tzelepis K, Costa ASH, Vohra S, Medina-Perez P, et al. Glutaminolysis is a metabolic dependency in FLT3(ITD) acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition. Blood. 2018;131:1639–53.
- 56.Wangensteen KJ, Wang YJ, Dou ZX, Wang AW, Mosleh-Shirazi E, Horlbeck MA, et al. Combinatorial genetics in liver repopulation and carcinogenesis with a in vivo CRISPR activation platform. Hepatology. 2018;68:663–76.
- 57.Bester AC, Lee JD, Chavez A, Lee YR, Nachmani D, Vora S, et al. An integrated genome-wide CRISPRa approach to functionalize lncRNAs in drug resistance. Cell. 2018;173:649–64.
- 58.Manguso RT, Pope HW, Zimmer MD, Brown FD, Yates KB, Miller BC, et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 2017;547:413–8.
- 59.Pan D, Kobayashi A, Jiang P, de Andrade LF, Tay RE, Luoma AM, et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science. 2018;359:770–5.
- 60.LaFleur MW, Nguyen TH, Coxe MA, Yates KB, Trombley JD, Weiss SA, et al. A CRISPR-Cas9 delivery system for in vivo screening of genes in the immune system. Nat Commun. 2019;10:1668. https://doi.org/10.1038/s41467-019-09656-2.
- 61.Yin H, Xue W, Anderson DG. CRISPR-Cas: a tool for cancer research and therapeutics. Nat Rev Clin Oncol. 2019;16:281–95.
- 62.Rogers ZN, McFarland CD, Winters IP, Naranjo S, Chuang CH, Petrov D, et al. A quantitative and multiplexed approach to uncover the fitness Landscape of tumor suppression in vivo. Nat Methods. 2017;14:737–42.
- 63.Chiou SH, Winters IP, Wang J, Naranjo S, Dudgeon C, Tamburini FB, et al. Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing. Gene Dev. 2015;29:1576–85.
- 64.Ma J, Koster J, Qin Q, Hu SG, Li W, Chen CH, et al. CRISPR-DO for genome-wide CRISPR design and optimization. Bioinformatics. 2016;32:3336–8.
- 65.Ma XL, Zhang QY, Zhu QL, Liu W, Chen Y, Qiu R, et al. A robust CRISPR/Cas9 system for convenient, high-efficiency multiplex genome editing in monocot and dicot plants. Mol Plant. 2015;8:1274–84.
- 66.Richardson CD, Ray GJ, DeWitt MA, Curie GL, Corn JE. Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. Nat Biotechnol. 2016;34:339–44.
- 67.Haeussler M, Schonig K, Eckert H, Eschstruth A, Mianne J, Renaud JB, et al. Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biol. 2016;17:148. https://doi.org/10.1186/s13059-016-1012-2.
- 68.Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016;34:184–91.
- 69.Zhu SY, Li W, Liu JZ, Chen CH, Liao Q, Xu P, et al. Genome-scale deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR-Cas9 library. Nat Biotechnol. 2016;34:1279–86.
- 70.Abudayyeh OO, Gootenberg JS, Franklin B, Koob J, Kellner MJ, Ladha A, et al. A cytosine deaminase for programmable single-base RNA editing. Science. 2019;365:382–6.
- 71.Ford K, McDonald D, Mali P. Functional genomics via CRISPR-Cas. J Mol Biol. 2019;431:48–65.
- 72.Jacobson EF, Tzanakakis ES. Human pluripotent stem cell differentiation to functional pancreatic cells for diabetes therapies: innovations, challenges and future directions. J Biol Eng. 2017;11:21. https://doi.org/10.1186/s13036-017-0066-3.
- 73.Mohr SE, Hu YH, Ewen-Campen B, Housden BE, Viswanatha R, Perrimon N. CRISPR guide RNA design for research applications. FEBS J. 2016;283:3232–8.
- 74.Jagadevan S, Banerjee A, Banerjee C, Guria C, Tiwari R, Baweja M, et al. Recent developments in synthetic biology and metabolic engineering in microalgae towards biofuel production. Biotechnol Biofuels. 2018;11:185. https://doi.org/10.1186/s13068-018-1181-1.
- 75.Doench JG. Am I ready for CRISPR? A user’s guide to genetic screens. Nat Rev Genet. 2018;19:67–80.
- 76.Li W, Xu H, Xiao TF, Cong L, Love MI, Zhang F, et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol. 2014;15:554.
- 77.Wang BB, Wang M, Zhang WB, Xiao TF, Chen CH, Wu A, et al. Integrative analysis of pooled CRISPR genetic screens using MAGeCKFlute. Nat Protoc. 2019;14:756–80.
- 78.Fellmann C, Cowen BC, Lin PC, Doudna JA, Corn JE. Cornerstones of CRISPR-Cas in drug discovery and therapy. Nat Rev Drug Discov. 2017;16:89–100.
- 79.O’Neil NJ, Bailey ML, Hieter P. Synthetic lethality and cancer. Nat Rev Genet. 2017;18:613–23.
- 80.Kampmann M. CRISPRi and CRISPRa screens in mammalian cells for precision biology and medicine. ACS Chem Biol. 2018;13:406–16.
- 81.Chow RD, Chen SD. Cancer CRISPR screens in vivo. Trends Cancer. 2018;4:349–58.
This work was supported by the “Personalized Medicine Molecular Signature-based Drug Discovery and Development” Strategic Priority Research Program of the Chinese Academy of Sciences [XDA12020111], the National Science and Technology Major Project “Key New Drug Creation and Manufacturing Program” [2018ZX09711002-011-014 & 2018ZX09711002-004-011] and the National Natural Science Foundation of China . It was also partially supported by the Fudan-SIMM Joint Research Fund [FU-SIMM20172005].
- Division of Anti-tumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China
- Hui Xing
- & Ling-hua Meng
- University of Chinese Academy of Sciences, Beijing, 100049, China
- Hui Xing
- & Ling-hua Meng
Correspondence to Ling-hua Meng.
Rights and permissions
About this article
Cite this article
Xing, H., Meng, L. CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment. Acta Pharmacol Sin (2019) doi:10.1038/s41401-019-0322-9
- Received06 September 2019
- Accepted22 October 2019
- Published02 December 2019
- precision medicine
- drug target
- drug resistance
- synergistic lethality
Acta Pharmacologica Sinica
ISSN 1745-7254 (online)
Publish with us
Libraries & institutions
Advertising & partnerships
© 2019 Springer Nature Limited
Machine Learning That Works Like A Dream
A group of researchers have created a new artificial intelligence program for automatically classifying the sleep stages of mice that combines two popular machine learning methods. Dubbed “MC-SleepNet,” the algorithm achieved accuracy rates exceeding 96% and high robustness against noise in the biological signals. The use of this system for automatically annotating data can significantly assist sleep researchers when analyzing the results of their experiments.
Scientists who study sleep often use mice as animal models to better understand the ways the activity in the brain changes during the various phases. These phases can be classified as awake, REM (rapid eye movement) sleep, and non-REM sleep. Previously, researchers who monitored the brainwaves of sleeping mice ended up with mountains of data that needed to be laboriously labeled by hand, often by teams of students. This represented a major bottleneck in the research.
Now, they have introduced a program for automatically classifying the stage of sleep that a mouse experienced based on its electroencephalogram (EEG) and electromyogram (EMG) signals, which record electrical activity in the brain and body, respectively.
YOU MAY ALSO LIKE
6 months ago
2 years ago
5 months ago
2 years ago
4 months ago
7 months ago
PQ RECOMMENDED BOOK
Contribute & Collaborate
You can contribute your articles on emerging fields to Pioneering Minds. You can also collaborate with Pioneering Minds on patents within various categories of emerging fields like AI, Space Exploration, Nanomaterials, Autonomous Vehicles, DNA Editing, Robotics, IOT, Quantum Computing, Wearables, 3D Printing, Cryptocurrency, Energy Storage, Neurophotonics and other.
© 2017-2019 Pioneering Minds
How to induce magnetism in graphene
How to induce magnetism in graphene
December 10, 2019 by Karin Weinmann, Swiss Federal Laboratories for Materials Science and Technology
Graphene, a two-dimensional structure made of carbon, is a material with excellent mechanical, electronic and optical properties. However, it did not seem suitable for magnetic applications. Together with international partners, Empa researchers have now succeeded in synthesizing a unique nanographene predicted in the 1970s, which conclusively demonstrates that carbon in very specific forms has magnetic properties that could permit future spintronic applications. The results have just been published in the renowned journal Nature Nanotechnology.
Depending on the shape and orientation of their edges, graphene nanostructures (also known as nanographenes) can have very different properties—for example, they may exhibit conducting, semiconducting or insulating behavior. However, one property has so far been elusive: magnetism. Together with colleagues from the Technical University in Dresden, Aalto University in Finland, Max Planck Institute for Polymer Research in Mainz and University of Bern, Empa researchers have now succeeded in building a nanographene with magnetic properties that could be a decisive component for spin-based electronics functioning at room temperature.
Graphene consists only of carbon atoms, but magnetism is a property hardly associated with carbon. So how is it possible for carbon nanomaterials to exhibit magnetism? To understand this, we need to take a trip into the world of chemistry and atomic physics.
The carbon atoms in graphene are arranged in a honeycomb structure. Each carbon atom has three neighbors, with which it forms alternating single or double bonds. In a single bond, one electron from each atom—a so-called valence electron—binds with its neighbor; while in a double bond, two electrons from each atom participate. This alternating single and double bond representation of organic compounds is known as the Kekulé structure, named after the German chemist August Kekulé who first proposed this representation for one of the simplest organic compound, benzene (Figure 1). The rule here is that electron pairs inhabiting the same orbital must differ in their direction of rotation—the so-called spin—a consequence of the quantum mechanical Pauli’s exclusion principle.
“However, in certain structures made of hexagons, one can never draw alternating single and double bond patterns that satisfy the bonding requirements of every carbon atom. As a consequence, in such structures, one or more electrons are forced to remain unpaired and cannot form a bond,” explains Shantanu Mishra, who is researching novel nanographenes in the Empa nanotech@surfaces laboratory headed by Roman Fasel. This phenomenon of involuntary unpairing of electrons is called “topological frustration” (Figure 1).
But what does this have to do with magnetism? The answer lies in the “spins” of the electrons. The rotation of an electron around its own axis causes a tiny magnetic field, a magnetic moment. If, as usual, there are two electrons with opposite spins in an orbital of an atom, these magnetic fields cancel each other. If, however, an electron is alone in its orbital, the magnetic moment remains—and a measurable magnetic field results.
This alone is fascinating. But in order to be able to use the spin of the electrons as circuit elements, one more step is needed. One answer could be a structure that looks like a bow tie under a scanning tunneling microscope (Figure 2).
Two frustrated electrons in one molecule
Back in the 1970s, the Czech chemist Erich Clar, a distinguished expert in the field of nanographene chemistry, predicted a bow tie-like structure known as “Clar’s goblet” (Figure 1). It consists of two symmetrical halves and is constructed in such a way that one electron in each of the halves must remain topologically frustrated. However, since the two electrons are connected via the structure, they are antiferromagnetically coupled—that is, their spins necessarily orient in opposite directions.
In its antiferromagnetic state, Clar’s goblet could act as a “NOT” logic gate: if the direction of the spin at the input is reversed, the output spin must also be forced to rotate.
However, it is also possible to bring the structure into a ferromagnetic state, where both spins orient along the same direction. To do this, the structure must be excited with a certain energy, the so-called exchange coupling energy, so that one of the electrons reverses its spin.
In order for the gate to remain stable in its antiferromagnetic state, however, it must not spontaneously switch to the ferromagnetic state. For this to be possible, the exchange coupling energy must be higher than the energy dissipation when the gate is operated at room temperature. This is a central prerequisite for ensuring that a future spintronic circuit based on nanographenes can function faultlessly at room temperature.
From theory to reality
So far, however, room-temperature stable magnetic carbon nanostructures have only been theoretical constructs. For the first time, the researchers have now succeeded in producing such a structure in practice, and showed that the theory does correspond to reality. “Realizing the structure is demanding, since Clar’s goblet is highly reactive, and the synthesis is complex,” explains Mishra. Starting from a precursor molecule, the researchers were able to realize Clar’s goblet in ultrahigh vacuum on a gold surface, and experimentally demonstrate that the molecule has exactly the predicted properties.
Importantly, they were able to show that the exchange coupling energy in Clar’s goblet is relatively high at 23 meV (Figure 2), implying that spin-based logic operations could therefore be stable at room temperature. “This is a small but important step toward spintronics,” says Roman Fasel.
More information: S. Mishra, et al. Topological frustration induces unconventional magnetism in a nanographene, Nature Nanotechnology (2019).
Journal information: Nature Nanotechnology
Heat energy leaps through empty space, thanks to quantum weirdness 6 hours agoResearch confirms timing of tropical glacier melt at the end of the last ice age 5 hours agoRevealing the physics of the Sun with Parker Solar Probe 3 hours agoEarth was stressed before dinosaur extinction 3 hours agoJeff Bezos’s Blue Origin rocket makes 12th test flight 3 hours ago
Phys.org™ (formerly Physorg.com) is a leading web-based science, research and technology news service which covers a full range of topics.
Phys.org is a part of Science X network. With global reach of over 5 million monthly readers and featuring dedicated websites for hard sciences, technology, smedical research and health news, the Science X network is one of the largest online communities for science-minded people.Read moreclose
What do you think about this particular story? Your feedback will go directly to Science X editors.
Phys.org™ (formerly Physorg.com) is a leading web-based science, research and technology news service which covers a full range of topics.
Phys.org is a part of Science X network. With global reach of over 5 million monthly readers and featuring dedicated websites for hard sciences, technology, smedical research and health news, the Science X network is one of the largest online communities for science-minded people.Read more
Science X Daily and the Weekly Email Newsletter are free features that allow you to receive your favorite sci-tech news updates in your email inboxSubscribe